CN116606377A - 靶向cd24和cd47的双特异性抗体融合蛋白及其制备方法与应用 - Google Patents
靶向cd24和cd47的双特异性抗体融合蛋白及其制备方法与应用 Download PDFInfo
- Publication number
- CN116606377A CN116606377A CN202310421574.5A CN202310421574A CN116606377A CN 116606377 A CN116606377 A CN 116606377A CN 202310421574 A CN202310421574 A CN 202310421574A CN 116606377 A CN116606377 A CN 116606377A
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- bispecific antibody
- ppab001
- seq
- antibody fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 97
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 85
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 title claims abstract description 52
- 102100038081 Signal transducer CD24 Human genes 0.000 title claims abstract description 52
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title claims abstract description 49
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000018883 protein targeting Effects 0.000 title claims abstract description 6
- 230000027455 binding Effects 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 23
- 229940079593 drug Drugs 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 229940041181 antineoplastic drug Drugs 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
- 239000000411 inducer Substances 0.000 claims description 6
- -1 lantelone Chemical compound 0.000 claims description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical group FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- 229930192392 Mitomycin Natural products 0.000 claims description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 108010084455 Zeocin Proteins 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000002254 cytotoxic agent Substances 0.000 claims description 5
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 5
- 229960001428 mercaptopurine Drugs 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 229960004857 mitomycin Drugs 0.000 claims description 5
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 3
- 102000015790 Asparaginase Human genes 0.000 claims description 3
- 108010024976 Asparaginase Proteins 0.000 claims description 3
- 229940127399 DNA Polymerase Inhibitors Drugs 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000000588 Interleukin-2 Human genes 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 102000004243 Tubulin Human genes 0.000 claims description 3
- 108090000704 Tubulin Proteins 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims description 3
- 229960004176 aclarubicin Drugs 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 229940110282 alimta Drugs 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229960003437 aminoglutethimide Drugs 0.000 claims description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 3
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 229940046836 anti-estrogen Drugs 0.000 claims description 3
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 3
- 239000000051 antiandrogen Substances 0.000 claims description 3
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 239000003886 aromatase inhibitor Substances 0.000 claims description 3
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 3
- 229960003272 asparaginase Drugs 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 239000012620 biological material Substances 0.000 claims description 3
- 230000008512 biological response Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 229960005395 cetuximab Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960000684 cytarabine Drugs 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 229960000640 dactinomycin Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 3
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229950004203 droloxifene Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 239000000328 estrogen antagonist Substances 0.000 claims description 3
- 229960000255 exemestane Drugs 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229940022353 herceptin Drugs 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 3
- 229960003881 letrozole Drugs 0.000 claims description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 3
- 238000001668 nucleic acid synthesis Methods 0.000 claims description 3
- HNKLPNDFOVJIFG-UHFFFAOYSA-N oxalic acid;platinum Chemical compound [Pt].OC(=O)C(O)=O HNKLPNDFOVJIFG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 150000003058 platinum compounds Chemical class 0.000 claims description 3
- 229960003171 plicamycin Drugs 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000002212 purine nucleoside Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 229940063683 taxotere Drugs 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 3
- 229960002066 vinorelbine Drugs 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 229940125697 hormonal agent Drugs 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Natural products CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 28
- 102000004169 proteins and genes Human genes 0.000 abstract description 15
- 210000004881 tumor cell Anatomy 0.000 abstract description 11
- 230000035755 proliferation Effects 0.000 abstract description 6
- 238000000746 purification Methods 0.000 abstract description 6
- 238000001042 affinity chromatography Methods 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 46
- 206010028980 Neoplasm Diseases 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 18
- 210000002540 macrophage Anatomy 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 14
- 239000002609 medium Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 206010057249 Phagocytosis Diseases 0.000 description 8
- 230000008782 phagocytosis Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 108091006020 Fc-tagged proteins Proteins 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 101710098610 Leukocyte surface antigen CD47 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000011789 NOD SCID mouse Methods 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 230000006819 RNA synthesis Effects 0.000 description 2
- 101150036449 SIRPA gene Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229930188522 aclacinomycin Natural products 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000004005 nitrosamines Chemical class 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229940122004 CD47 antagonist Drugs 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N N-methylaminoacetic acid Natural products C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101000884281 Rattus norvegicus Signal transducer CD24 Proteins 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100027164 Sialic acid-binding Ig-like lectin 10 Human genes 0.000 description 1
- 101710143293 Sialic acid-binding Ig-like lectin 10 Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000009950 gastric cancer growth Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了靶向CD24和CD47的双特异性抗体融合蛋白及其制备方法与应用。本发明的双特异性抗体融合蛋白包含CD24抗体重链、CD24抗体轻链及CD47‑Fc结合肽,其中CD24抗体重链的恒定区与CD47‑Fc结合肽的Fc段通过“锁钥结构”连接,该融合蛋白能够同时与CD47、CD24结合。本发明的双特异性抗体融合蛋白兼具anti‑CD24和CV1‑hFc的功能,能阻断CD47及CD24介导的肿瘤细胞的增殖。此外,该双特异性抗体融合蛋白PPAB001可以像传统的IgG分子一样,最大程度地保留了传统单克隆抗体结构,由于Fc片段的存在,可通过Protein A柱亲和层析法纯化,利于大规模的生产纯化。
Description
技术领域
本发明涉及肿瘤免疫学领域,具体地说,涉及一种靶向CD24和CD47的双特异性抗体融合蛋白及其制备方法与应用。
背景技术
恶性肿瘤是严重危害人类健康的疾病,在各种致死性的疾病中高居第二位。近年来,恶性肿瘤的发病率明显上升,同时,其治疗效果较差,晚期易发生转移,预后不佳。目前临床上,所采用的常规治疗方法如放化疗和手术治疗很大程度缓解了疼痛,但这些疗法的副作用及局限性仍很大,疗效难以进一步提高。
肿瘤的发生发展是个多因素多机制多种因子参与的过程。CD47即整合素相关蛋白(Integrin-Associated Protein,IAP),表达于细胞表面,可结合巨噬细胞表面的信号调节蛋白-α(Signal-RegμLatory Proteinα,SIRPα)进而磷酸化SIRPα的胞质内免疫受体酪氨酸抑制性基序(Immunoreceptor Tyrosine-based Inhibition Motifs,ITIMs),招募磷酸酶SHP-1后向巨噬细胞发出“别吃我”的抑制性信号。CD47分子在肿瘤细胞表面的广泛表达抑制了巨噬细胞对肿瘤细胞的吞噬效应。据此,研究人员开发了可激活巨噬细胞吞噬效应的CD47拮抗剂(CD47 antagonists)。CD47拮抗剂将通过封闭CD47和SIRPα结合而激活巨噬细胞的吞噬作用,增强抗肿瘤免疫反应,最终达到抑制肿瘤生长的目的。
CD24又名热稳定抗原(Heat Stable Antigen,HSA),是一个含有31个氨基酸的短肽。作为一种细胞黏附分子,CD24的糖基化高度多变且和细胞类型相关,高度糖基化的CD24通过磷脂酰肌醇(Glycosyl-Phoshphatidyl-Inositol,GPI)锚定在细胞膜内的脂质筏上。研究发现CD24在乳腺癌、卵巢癌及肺癌等多种肿瘤细胞表面过表达。它可与巨噬细胞表面表达的抑制性受体Siglec-10结合发出“别吃我”的信号从而限制了巨噬细胞的吞噬作用,这种免疫抑制性信号往往通过和经典的CD47信号互补的方式发挥作用,因此CD24可能是肿瘤免疫治疗的一个新靶点。进一步研究发现,抗CD24的抗体可有效激活巨噬细胞吞噬作用的活性。为此,CD24不仅是一个新发现的免疫检查点,同时也是潜在的抗肿瘤药物作用靶点。另外,研究发现人红细胞表面不表达CD24分子,故CD24靶向药物不存在潜在的血液毒性风险。
由此可见,如果能同时阻断CD47和CD24,不但可以抑制CD24信号激活导致的肿瘤的侵袭和转移,也将阻断CD47和CD24介导的肿瘤抑制性信号,激活对肿瘤的免疫反应,故可能会比单独阻断CD24或CD47有更好的抑制肿瘤生长增殖的协同作用,对肿瘤的治疗将具有重要意义。
然而,单抗联合应用具有多方面的限制。首先,临床上应用两种抗体的安全性和效果至今未有详尽的报道,可能存在安全风险;另外,联合应用两种抗体也存在调节障碍和造价太高的缺陷,限制了其临床应用。
因此,采用基因工程技术构建一个可以同时阻断两个靶点的双特异性抗体融合蛋白,既能阻断CD24,又能阻断CD47,进而更有效地抑制肿瘤的生长和增殖,成为亟待解决的技术问题。
发明内容
本发明的目的是提供一种靶向CD24和CD47的双特异性抗体融合蛋白及其制备方法与应用。
为了实现本发明目的,第一方面,本发明提供一种靶向CD24和CD47的双特异性抗体融合蛋白CD47/CD24-BsAb-Ig(记为PPAB001),所述融合蛋白包含CD24抗体重链、CD24抗体轻链以及CD47-Fc结合肽;
其中,CD24抗体重链的恒定区与CD47-Fc结合肽的Fc段通过“锁钥结构”连接;
所述融合蛋白能够同时与CD47、CD24结合。
进一步地,所述CD24抗体轻链包含SEQ ID NO:14所示的氨基酸序列,所述CD24抗体重链包含SEQ ID NO:16所示的氨基酸序列,所述CD47-Fc结合肽包含SEQ ID NO:18所示的氨基酸序列。
第二方面,本发明提供所述融合蛋白的制备方法,包括如下步骤:
S1、分别构建含有SEQ ID NO:13、SEQ ID NO:15及SEQ ID NO:17所示的核苷酸序列的载体,并将其共转染至宿主细胞中进行培养,筛选稳定表达目标融合蛋白的细胞克隆;
S2、对细胞培养物进行分离纯化,得到目标融合蛋白。
进一步地,所述载体可以是真核表达载体pcDNA3.1。
进一步地,所述宿主细胞可以是CHO-K1细胞。
进一步地,用含600μg/mL G418和250μg/mL Zeocin的选择培养基筛选稳定表达目标融合蛋白的细胞克隆。
第三方面,本发明提供编码所述融合蛋白的核酸分子。
第四方面,本发明提供含有所述核酸分子的生物材料,所述生物材料包括但不限于重组DNA、表达盒、转座子、质粒载体、病毒载体、工程菌或转基因细胞系。
第五方面,本发明提供含有所述融合蛋白的组合物,所述组合物任选包含抗肿瘤制剂。
所述抗肿瘤制剂选自如下A~E中的至少一种:
A、细胞毒类药物,包括:(1)作用于DNA化学结构的药物:烷化剂如氮芥类、亚硝尿类、甲基磺酸酯类;铂类化合物如顺铂、卡铂和草酸铂等;丝裂霉素(MMC);(2)影响核酸合成的药物:二氢叶酸还原酶抑制剂如甲氨喋呤(MTX)和Alimta等;胸腺核苷合成酶抑制剂如氟尿嘧啶类(5FU、FT-207、卡培他滨)等;嘌呤核苷合成酶抑制剂,如6-巯基嘌呤(6-MP)和6-TG等;核苷酸还原酶抑制剂,如羟基脲(HU)等;DNA多聚酶抑制剂如阿糖胞苷(Ara-C)和健择(Gemz)等;(3)作用于核酸转录的药物:选择性作用于DNA模板,抑制DNA依赖RNA聚合酶,从而抑制RNA合成的药物,如放线菌素D、柔红霉素、阿霉素、表阿霉素、阿克拉霉素、光辉霉素等;(4)作用于微管蛋白合成的药物,如紫杉醇、泰索帝、长春花碱、长春瑞滨、鬼臼硷类、高三尖杉酯碱;(5)其他细胞毒药,如门冬酰胺酶,主要抑制蛋白质的合成;
B、激素类药物,包括:(1)抗雌激素,如三苯氧胺、屈洛昔芬、依西美坦等;(2)芳香化酶抑制剂,如氨鲁米特、兰特隆、来曲唑、瑞宁德等;抗雄激素:(3)氟它氨RH-LH激动剂/拮抗剂,如诺雷德、依那通等;
C、生物反应调节剂:包括:(1)主要通过机体免疫功能抑制肿瘤干扰素,如白细胞介素-2;(2)胸腺肽类;
D、单克隆抗体,如西妥昔Cetuximab(C225);赫赛汀单抗(Trastuzumab)贝伐单抗(Avastin);
E、其他包括一些目前机制不明和有待进一步研究的药物:包括:(1)细胞分化诱导剂,如维甲类;(2)细胞凋亡诱导剂。
第六方面,本发明提供所述融合蛋白或所述组合物在制备抗肿瘤药物中的应用。
所述肿瘤包括但不限于乳腺癌、卵巢癌、结肠癌、肺癌等,优选乳腺癌、卵巢癌。
借由上述技术方案,本发明至少具有下列优点及有益效果:
本发明采用基因工程技术构建了可以同时阻断两个靶点的双特异性抗体融合蛋白CD47/CD24-BsAb-Ig,包含抗CD24侧的重链、抗CD24侧的轻链以及抗CD47侧的Fc融合蛋白,该双特异性抗体融合蛋白既能阻断CD24,又能阻断CD47,进而更有效地抑制肿瘤的生长和增殖。
采用本发明提供的制备方法制备的所述双特异性抗体融合蛋白,可同时具有anti-CD24和CV1-hFc的功能,能阻断CD47及CD24介导的肿瘤细胞的增殖。此外,该双特异性抗体融合蛋白像传统的IgG分子一样,最大程度地保留了传统单克隆抗体结构,由于有Fc片段的存在,可以用普通的Protein A柱亲和层析法纯化,利于大规模的生产纯化。
附图说明
图1为本发明较佳实施例中双特异性抗体融合蛋白结构示意图及凝胶过滤层析纯化结果;其中,A为anti-CD24蛋白,B为双特异性抗体融合蛋白PPAB001,C为CV1-hFc蛋白,D为各组分分子量大小的分析结果。
图2为本发明较佳实施例中双特异性抗体融合蛋白的SDS-PAGE验证试验;从左至右,第一泳道为蛋白质分子量对照品,第二泳道为CV1-hFc蛋白,第三泳道为anti-CD24蛋白,第四泳道为双特异性抗体融合蛋白PPAB001。
图3为本发明较佳实施例中双特异性抗体融合蛋白与CD24及CD47结合活性实验结果。
图4为本发明较佳实施例中双特异性抗体融合蛋白与CD24及CD47双阳性细胞结合的流式细胞术验证结果。
图5为本发明较佳实施例中双特异性抗体融合蛋白激活巨噬细胞的免疫荧光实验。其中,A为免疫荧光观察巨噬细胞对乳腺癌细胞吞噬作用(荧光显微镜放大倍数400倍),B为统计学分析乳腺癌细胞被吞噬的比率。
图6为本发明较佳实施例中双特异性抗体融合蛋白抑制荷瘤小鼠4T-1细胞肿瘤生成实验。
图7为本发明较佳实施例中双特异性抗体融合蛋白抑制荷瘤小鼠SK-OV-3细胞肿瘤生成实验。
图8为本发明较佳实施例中双特异性抗体融合蛋白对荷瘤小鼠MFC细胞肿瘤生成的影响。
具体实施方式
本发明提供一种抗CD47和CD24的双特异性抗体融合蛋白及其制备方法,所述双特异性抗体融合蛋白既可以抑制CD24,也能拮抗CD47,可用于制备抗肿瘤药物。
本发明采用如下技术方案:
第一方面,本发明提供一种抗CD47和CD24的双特异性抗体融合蛋白CD24/CD47-BsAb-Ig(即PPAB001),所述双特异性抗体融合蛋白包含抗CD24侧的重链、抗CD24侧的轻链以及抗CD47侧的Fc融合蛋白。
所述抗CD24侧的重链、抗CD24侧的轻链以及抗CD47侧的Fc融合蛋白可通过在CHO细胞内形成二硫键组成得到一种即可抑制CD24,又可拮抗CD47的双特异性抗体融合蛋白。
为了避免在上述元件的组成过程中发生抗CD24侧抗体或抗CD47侧融合蛋白的自我连接或组合,本发明对上述抗CD24侧的重链和抗CD47侧的Fc融合蛋白中的恒定区CH3区进行了定点突变,具体如下:在抗CD24侧重链恒定区CH3引入一个突变,包括SEQ ID NO:2中第249位由苏氨酸转变为色氨酸。在PPAB001的抗CD47侧Fc区引入三个突变,包括SEQ IDNO:12中第152位由苏氨酸转变为丝氨酸,第154位亮氨酸转变为丙氨酸及第193位酪氨酸转变为缬氨酸。经突变后抗CD47侧Fc段和抗CD24侧重链恒定区可通过这些氨基酸形成类似于“锁钥结构(Knob-in-hole)”的结合模式,大大增加了正确配对的几率,降低了形成自身配对的可能性。
基于上述调整,所述双特异性抗体融合蛋白具体包含SEQ ID NO:14、SEQ ID NO:16及SEQ ID NO:18所示的氨基酸序列。
第二方面,本发明提供前述双特异性抗体融合蛋白的制备方法,包括如下步骤:
S1、构建分别含有SEQ ID NO:13、SEQ ID NO:15及SEQ ID NO:17所示的核苷酸序列的载体,并将其用脂质体法共转染至宿主细胞中进行培养,筛选稳定表达双特异性抗体融合蛋白的细胞克隆;
S2、对细胞培养物进行分离纯化,得到双特异性抗体融合蛋白PPAB001。
需要说明的是,本发明所述的载体可为本领域常规使用的载体,例如pCDNA3.1、pDHFF等。表达载体中包括连接有合适的转录和翻译调节序列的融合DNA序列。
可选地,如在本发明的具体实施方式中,使用真核表达载体pcDNA3.1。
进一步地,用于表达所述双特异性抗体融合蛋白的宿主细胞可为原核细胞,例如DH5α、BL21(DE3)、TG1等;也可为哺乳动物或昆虫宿主细胞,COS、CHO、NSO、sf9及sf21等均可适用于本发明。
作为优选,本发明选择CHO-K1细胞(ATCC)作为宿主细胞进行双特异性抗体融合蛋白的表达。
进一步地,宿主细胞的培养条件为本领域常规培养条件,例如使用含10%血清的DMEM培养基进行培养。
进一步地,S2中,用含600μg/mL G418和250μg/mL Zeocin的选择培养基筛选稳定表达双特异性抗体融合蛋白的细胞克隆。利用上述方法,可将双特异性抗体融合蛋白纯化为基本均一的物质,例如在SDS-PAGE电泳上为单一条带。更进一步地,可以利用亲和层析的方法对本发明公开的双特异性抗体融合蛋白进行分离纯化,根据所利用的亲和柱的特性,可以使用常规方法例如高盐缓冲液、改变pH等方法洗脱结合在亲和柱上的双特异性抗体融合蛋白。
本发明对PPAB001进行亲和力检测,发现其完好地保留了anti-CD24和CV1-hFc的亲和力。利用PPAB001进行下一步实验,包括肿瘤细胞增殖、体内抑瘤和促巨噬细胞吞噬等实验,结果表明,本发明公开的双特异性抗体融合蛋白PPAB001同时具有anti-CD24和CV1-hFc的功能,它能够阻断CD47及CD24介导的肿瘤细胞的增殖。此外,该双特异性抗体融合蛋白PPAB001可以和传统的IgG分子一样,最大程度地保留了传统单克隆抗体结构,由于有Fc片段的存在,可以用普通的Protein A柱亲和层析法纯化,利于大规模的生产纯化。实验表明,在相同剂量下,双特异性抗体融合蛋白PPAB001具有明显优于anti-CD24的抗肿瘤治疗效果。
第三方面,基于前述技术方案,可同时表达SEQ ID NO:14、SEQ ID NO:16及SEQ IDNO:18所示的氨基酸序列的宿主细胞,以及包括分别含有SEQ ID NO:13、SEQ ID NO:15及SEQ ID NO:17所示核苷酸序列的载体组合也在本发明的保护范围之内。
第四方面,本发明还提供含有前述双特异性抗体融合蛋白PPAB001的组合物。
本发明还提供前述双特异性抗体融合蛋白PPAB001或含有其的组合物在制备抗肿瘤药物中的应用。
本发明公开的上述双特异性抗体融合蛋白PPAB001,与药学上可以接受的辅料一起组成药物制剂组合物从而更稳定地发挥疗效,这些制剂可以保证本发明公开的全人源抗体氨基酸核心序列的构像完整性,同时还要保护蛋白质的多官能团防止其降解(包括但不限于凝聚、脱氨或氧化)。通常情况下,对于液体制剂,通常可以在2-8℃条件下保存至少稳定一年,对于冻干制剂,在30℃至少六个月保持稳定。在这里制剂可为制药领域常用的混悬、水针、冻干等制剂,优选水针或冻干制剂,对于本发明公开的上述全人源抗体的水针或冻干制剂,药学上可以接受的辅料包括表面活性剂、溶液稳定剂、等渗调节剂和缓冲液之一或其组合,其中表面活性剂包括非离子型表面活性剂如聚氧乙烯山梨醇脂肪酸酯(吐温20或80);poloxamer(如poloxamer 188);Triton;十二烷基硫酸钠(SDS);月桂硫酸钠;十四烷基、亚油基或十八烷基肌氨酸;Pluronics;MONAQUATTM等,其加入量应使双特异性抗体融合蛋白的颗粒化趋势最小,溶液稳定剂可以为糖类,包括还原性糖和非还原性糖,氨基酸类包括谷氨酸单钠或组氨酸,醇类包括三元醇、高级糖醇、丙二醇、聚乙二醇之一或其组合,溶液稳定剂的加入量应该使最后形成的制剂在本领域的技术人员认为达到稳定的时间内保持稳定状态,等渗调节剂可以为氯化钠、甘露醇之一,缓冲液可以为TRIS、组氨酸缓冲液、磷酸盐缓冲液之一。
上述制剂为包含双特异性抗体融合蛋白的组合物,在对包括人在内的动物给药后,抗肿瘤效果明显。具体来讲,对肿瘤的预防和/或治疗有效,可以作为抗肿瘤药物使用。
本发明所述的抗肿瘤药物,指具有抑制和/或治疗肿瘤的药物,可以包括伴随肿瘤生长相关症状发展的延迟和/或这些症状严重程度的降低,它进一步还包括已存在的肿瘤生长伴随症状的减轻并防止其他症状的出现,并减少或防止转移。
本发明中双特异性抗体融合蛋白PPAB001及含有其的组合物在对包括人在内的动物给药,给药剂量因病人的年龄和体重,疾病特性和严重性,以及给药途径而异,可以参考动物实验的结果和种种情况,总给药量不能超过一定范围。
本发明提供的双特异性抗体融合蛋白PPAB001及含有其的组合物还可以与其他的抗肿瘤药联合给药,用于肿瘤的治疗,这些抗肿瘤药包括:
1、细胞毒类药物
(1)作用于DNA化学结构的药物:烷化剂如氮芥类、亚硝尿类、甲基磺酸酯类;铂类化合物如顺铂、卡铂和草酸铂等;丝裂霉素(MMC);(2)影响核酸合成的药物:二氢叶酸还原酶抑制剂如甲氨喋呤(MTX)和Alimta等;胸腺核苷合成酶抑制剂如氟尿嘧啶类(5FU、FT-207、卡培他滨)等;嘌呤核苷合成酶抑制剂如6-巯基嘌呤(6-MP)和6-TG等;核苷酸还原酶抑制剂如羟基脲(HU)等;DNA多聚酶抑制剂如阿糖胞苷(Ara-C)和健择(Gemz)等;(3)作用于核酸转录的药物:选择性作用于DNA模板,抑制DNA依赖RNA聚合酶,从而抑制RNA合成的药物,如放线菌素D、柔红霉素、阿霉素、表阿霉素、阿克拉霉素、光辉霉素等;(4)主要作用于微管蛋白合成的药物:紫杉醇、泰索帝、长春花碱、长春瑞滨、鬼臼硷类、高三尖杉酯碱;(5)其他细胞毒药:门冬酰胺酶主要抑制蛋白质的合成;
2、激素类,抗雌激素:三苯氧胺、屈洛昔芬、依西美坦等;芳香化酶抑制剂:氨鲁米特、兰特隆、来曲唑、瑞宁德等;抗雄激素:氟它氨RH-LH激动剂/拮抗剂:诺雷德、依那通等;
3、生物反应调节剂:主要通过机体免疫功能抑制肿瘤干扰素;白细胞介素-2;胸腺肽类;
4、单克隆抗体:西妥昔Cetuximab(C225);赫赛汀单抗(Trastuzumab)贝伐单抗(Avastin);
5、其他包括一些目前机制不明和有待进一步研究的药物;细胞分化诱导剂如维甲类;细胞凋亡诱导剂。
本发明提供的双特异性抗体融合蛋白PPAB001及其组合物可以与上述抗肿瘤药物之一或其组合联合用药。
以下实施例用于说明本发明,但不用来限制本发明的范围。若未特别指明,实施例均按照常规实验条件,如Sambrook等分子克隆实验手册(Sambrook J&Russell DW,Molecular Cloning:a Laboratory Manual,2001),MolecμLar Cloning(Sambrook,J.,Fritsch,E.F.and Maniais,T.,1989):A Laboratory Manual,2nd edition,Cold springHarbor Laboratory Press,或按照制造厂商说明书建议的条件。
本发明中所涉及的术语及简称如下:
PPAB001:靶向CD47和CD24的双特异性抗体融合蛋白;
anti-CD24:抗CD24的单克隆抗体;
CV1-hFc:信号调节蛋白-α突变体可结晶片段融合蛋白;
CD47:整合素相关蛋白;
IgG:免疫球蛋白G;
ELISA:酶联免疫吸附试验;
SDS-PAGE:十二烷基磺酸钠-聚丙烯酰胺凝胶电泳。
实施例1人抗体轻、重链恒定区和Fc区基因的克隆
用淋巴细胞分离液分离健康人淋巴细胞,用Trizol试剂(Invitrogen公司产品)提取总RNA,根据文献(Cell,1980,22:197-207)和文献(Nucleic Acids Research,1982,10:4071-4079)报道的序列分别设计引物扩增IgG1型抗体重链和轻链恒定区基因,PCR反应均采用热启动,反应条件:94℃5分钟;94℃45秒,60℃45秒,72℃70秒,30个循环;72℃10分钟。PCR产物经琼脂糖凝胶电泳纯化回收并克隆到pGEM-T载体(Promega公司产品)中,测序验证后确认获得了正确的克隆。SEQ ID NO:1和SEQ ID NO:2分别为重链恒定区(CH)的核苷酸和氨基酸序列。SEQ ID NO:3和SEQ ID NO:4分别为轻链恒定区(CL)的核苷酸和氨基酸序列。SEQ ID NO:11和SEQ ID NO:12分别为恒定区Fc段(Fc)的核苷酸和氨基酸序列。将正确的克隆记作pGEM-T/CH、pGEM-T/CL、pGEM-T/Fc。
实施例2双特异性抗体融合蛋白PPAB001的构建
具体构建方法:anti-CD24是通过杂交瘤细胞技术筛选后并对抗体的恒定区进行人源化改造而获得的,全基因合成anti-CD24的重、轻链可变区基因,CV1的序列参见Science 341,88(2013)。Anti-CD24的重链可变区与人IgG1抗体的重链恒定区连接,组成了PPAB001的抗CD24侧重链基因;PCR克隆出CV1与人IgG1抗体的重链恒定区Fc段连接,组成了PPAB001的抗CD47侧融合蛋白基因。Anti-CD24的轻链可变区通过overlap PCR的方法与人IgG1抗体的轻链恒定区连接,组成了PPAB001的抗CD24侧轻链基因。将上述重、轻链基因及融合蛋白基因分别装入真核表达载体pcDNA3.1(Invitrogen公司产品)。上述质粒一起用脂质体法转染CHO-K1细胞(ATCC),并用含600μg/mL G418和250μg/mL Zeocin的选择培养基筛选稳定表达双特异性抗体融合蛋白的细胞克隆。利用Protein A柱通过亲和层析从细胞培养物的上清纯化双特异性抗体融合蛋白PPAB001。
双特异性抗体融合蛋白PPAB001的构建表达过程如下:
PPAB001抗CD24侧的重链和轻链可变区及抗CD47侧CV1分别为PPAB001VH,PPAB001VL及PPAB001CV1,经Overlap PCR合成后回收目的条带并克隆到pGEM-T载体中,筛选阳性克隆测序,分别得到pGEM-T/PPAB001VH(核苷酸序列和氨基酸序列见SEQ ID NO:5和SEQ ID NO:6),pGEM-T/PPAB001VL(核苷酸序列和氨基酸序列见SEQ ID NO:7和SEQ ID NO:8)及pGEM-T/PPAB001 CV1(核苷酸序列和氨基酸序列见SEQ ID NO:9和SEQ ID NO:10)。PCR采用Roche公司的高保真扩增系统,反应条件均为:95℃5分钟;94℃50秒,55℃45秒,72℃55秒,30个循环;72℃10分钟。
采用Overlap PCR将pGEM-T/PPAB001VH基因与pGEM-T/CH中的重链恒定区基因连接,并克隆到pGEM-T载体中,挑选正确克隆后以HindIII和EcoRI酶切,经琼脂糖凝胶电泳纯化回收目的片段,与同酶切的质粒pCDNA3.1(+)用T4 DNA连接酶进行连接,构建真核表达载体pCDNA3.1/ZEO(+)(PPAB001VHCH)(核苷酸序列和氨基酸序列见SEQ ID NO:15和SEQ IDNO:16)。
采用Overlap PCR将pGEM-T/PPAB001CV1基因与pGEM-T/Fc中的Fc段基因连接,并克隆到pGEM-T载体中,挑选正确克隆后以HindIII和EcoRI酶切,经琼脂糖凝胶电泳纯化回收目的片段,与同酶切的质粒pCDNA3.1(+)用T4 DNA连接酶进行连接,构建真核表达载体pCDNA3.1/ZEO(+)(PPAB001CV1-hFc)(核苷酸序列和氨基酸序列见SEQ ID NO:17和SEQ IDNO:18)。
采用Overlap PCR将pGEM-T/PPAB001VL中的PPAB001VL基因与pGEM-T/CL中的轻链恒定区基因相连,并克隆到pGEM-T载体中,挑选正确克隆后以HindIII和EcoRI酶切,经琼脂糖凝胶电泳纯化回收目的片段,与同酶切的质粒pCDNA3.1(+)用T4DNA连接酶进行连接,构建真核表达载体pCDNA3.1/ZEO(+)(PPAB001VLCL)(核苷酸序列和氨基酸序列如SEQ ID NO:13和SEQ ID NO:14所示)。
于3.5cm组织培养皿中接种3×105个CHO-K1细胞,细胞培养至90%-95%融合时进行转染:取质粒9μg(质粒pCDNA3.1(+)pCDNA3.1/ZEO(+)(PPAB001VHCH)3μg,pCDNA3.1/ZEO(+)(PPAB001VLCL)3μg,pCDNA3.1/ZEO(+)(PPAB001CV1-hFc)3μg)和20μLLipofectamine2000Reagent[Invitrogen公司产品]分别溶于500μL无血清DMEM培养基,室温静置5分钟,将以上2种液体混合,室温孵育20分钟以使DNA-脂质体复合物形成,其间用3mL无血清的DMEM培养基替换培养皿中的含血清培养基,然后将形成的DNA-脂质体复合物加入到板中,CO2孵箱培养4h后补加2mL含10%血清的DMEM完全培养基,置于CO2孵箱中继续培养。转染进行24h后细胞换含600μg/mL G418和250μg/mL Zeocin的选择培养基筛选抗性克隆。将筛选得到的高表达克隆用无血清培养基扩大培养,用Protein A亲和柱(GE公司产品)分离纯化双特异性抗体融合蛋白PPAB001。将PPAB001用PBS进行透析,最后以紫外吸收法定量。PPAB001的结构如图1B所示,左侧为PPAB001的抗CD24侧重链与轻链,右侧为PPAB001的抗CD47侧CV1的Fc融合蛋白。抗CD24蛋白的结构如图1A所示,CV1-hFc蛋白的结构如图1C所示。
实验例1双特异性抗体融合蛋白的凝胶过滤层析纯化试验
用平衡液(10mmol/L三羟甲基氨基甲烷盐酸盐(pH7.4)、150mmol/L氯化钠)平衡Superose 12 10/300GL柱子(GE公司产品)40mL后,将浓缩好的anti-CD24、PPAB001和CV1-hFc蛋白分别上样进行凝胶过滤层析纯化,以分析各组分的分子量大小。结果如图1D所示,抗体anti-CD24因分子量最大首先被洗脱出来,其次是双特异性抗体融合蛋白PPAB001,最后是融合蛋白CV1-hFc。
实验例2双特异性抗体融合蛋白纯度的验证试验
配制含有SDS 10%丙烯酰胺浓度的聚丙烯酰胺凝胶,将融合蛋白CV1-hFc,抗体anti-CD24及双特异性抗体融合蛋白PPAB001分别上样进行凝胶电泳试验,以分析各组分的纯度。结果如图2所示,PPAB001的纯度在90%以上。
实验例3双特异性抗体融合蛋白PPAB001与CD24和CD47的结合活性检测
将CD24(R&D公司产品)用0.05mmol/L碳酸钠-碳酸氢钠缓冲液(pH9.6)稀释成2μg/mL,50μL/孔,4℃包被过夜。10%脱脂奶室温封闭2h后,加入不同浓度的双特异性抗体融合蛋白,CV1-hFc和anti-CD24,50μL/孔,每个浓度取3个平行孔,室温孵育2h。弃上清液,PBS洗涤3次,加入按效价稀释好的HRP标记的CD47,50μL/孔,室温孵育45min。PBS充分洗涤后,TMB显色后,置酶标仪(酶标比色仪,美国BIO-Rad公司)中测定450nm吸光度(A450)值。实验结果如图3所示,图中纵坐标为450nm的光密度值(或称吸光度值),横坐标为抗体浓度的对数。CV1-hFc和anti-CD24仅能结合CD47或CD47,因此读值接近于0,而PPAB001组显示了随加入抗体浓度升高,相应OD值也增高的浓度依赖性效应。通过此试验证实了PPAB001既可结合CD47又可结合CD24的结合特性。实验结果表明,因双特异性抗体融合蛋白PPAB001可结合CD24也可结合CD47,而显现出浓度依赖效应呈S曲线。Anti-CD24和CV1-hFc因只能结合CD24或CD47,因此无结合活性。以上实验结果表明,构建的双特异性抗体融合蛋白PPAB001同时保留了亲本anti-CD24和CV1-hFc的结合活性。
实验例4流式细胞术分析
将CD24和CD47双阳性的乳腺癌BT-474细胞用2% FCS-PBS重悬成1×106个/mL,分别加入不同稀释度的PPAB001、anti-CD24、CV1-hFc和对照品IgG,置于4℃孵育1h,用2%FCS-PBS洗细胞2遍。再加入FITC标记的羊抗人IgG(H+L)的二抗于4℃孵育1h,用2% FCS-PBS洗细胞2遍后在流式细胞仪上进行分析,计算染色阳性细胞的百分数并比较各抗体的相对亲和力。实验结果如图4所示,图中横坐标为抗体的浓度,纵坐标为平均荧光强度。流式细胞术的结果表明,PPAB001对CD47和CD24双阳性的细胞结合具有浓度依赖性结合,呈现S曲线。Anti-CD24、CV1-hFc对CD47和CD24双阳性的细胞结合也具有浓度依赖性结合,但平均荧光强度较低。对照组为加入无关IgG组。实验结果表明,PPAB001可以结合CD24和CD47双阳性的BT-474细胞,即PPAB001可以同时结合细胞表面的CD24和CD47。
实验例5双特异性抗体融合蛋白PPAB001体外促进巨噬细胞对肿瘤细胞吞噬实验
利用无血清培养基灌洗小鼠腹腔,灌洗液制备鼠腹腔巨噬细胞,具体方法如下:对三只NOD-SCID小鼠提前5天腹腔注射1-2mL巯基乙酸盐培养基;5天后,颈椎脱臼法处死小鼠。用注射器抽取5mL含有双抗的RPMI-1640无血清培养基注入腹腔;用棉球轻揉腹部1-2分钟后吸取细胞悬液;1000rpm离心5min后,用无血清RPMI-1640培养基洗涤一次,再次离心,重悬细胞于含10%胎牛血清的RPMI-1640培养液中培养;接着利用荧光显微镜观察吞噬效果,其具体方法如下:以5×104个/孔的密度将腹腔来源的鼠巨噬细胞铺在24孔板中培养过夜;将5×106个BT474或BT474R或SK-OV-3细胞标记上羧基荧光素乙酰乙酸酯(CFSE)。将培养巨噬细胞的培养基更换为不添加血清的培养基,饥饿处理2h。每孔加入2×105个CFSE标记的肿瘤细胞;接下来加入以下组别的抗体,每组三个复孔,终浓度为10μg/mL:(1)IgG组;(2)CV1-hFc组;(3)anti-CD24组;(4)PPAB001组,37℃孵育2-3h。用培养基洗涤细胞三次,在共聚焦荧光显微镜下观察拍照,计算每100个巨噬细胞(三个视野)中CFSE阳性细胞的比率。实验结果如图5所示,其中A为PPAB001组处理后,较之CV1-hFc或anti-CD24单抗处理组,巨噬细胞对乳腺癌细胞吞噬效能显著增强;B为统计学数据,显示了PPAB001处理组被吞噬的细胞数目与CV1-hFc组或anti-CD24组比较有显著差异。实验结果表明,与对照组CV1-hFc和anti-CD24组相比,PPAB001可以有效促进巨噬细胞对肿瘤细胞的吞噬。
实验例6双特异性抗体融合蛋白PPAB001体内抑制肿瘤细胞生长实验
分别以乳腺癌4T-1细胞、卵巢癌SK-OV-3细胞或胃癌MFC细胞皮下接种雌性NOD-SCID鼠,在接种肿瘤细胞后待肿瘤组织达到80-120mm3,静脉注射以下4组,每组6只小鼠:①人IgG对照组;②anti-CD24;③CV1-hFc;④PPAB001。每周注射2次,共注射1周。给药过程中,每隔2日观察肿瘤生长情况,测量肿瘤大小以评价PPAB001的抑瘤作用。
实验结果分别如图6~图8所示,图6中横坐标为4T-1肿瘤的荷瘤小鼠接种肿瘤后的时间,纵坐标为肿瘤体积,箭头为两次药物注射的时间,表明经过一段时间的药物PPAB001治疗后,较之无关IgG治疗组及anti-CD24组或CV1-hFc组,PPAB001组显示了显著的肿瘤消退趋势,差异有统计学意义;图7中横坐标为SK-OV-3肿瘤的荷瘤小鼠接种肿瘤后的时间,纵坐标为肿瘤体积,箭头为两次药物注射的时间,表明经过一段时间的药物PPAB001治疗后,较之无关IgG治疗组及anti-CD24组或CV1-hFc组,PPAB001组显示了显著的肿瘤消退趋势,差异有统计学意义;图8中横坐标为MFC肿瘤的荷瘤小鼠接种肿瘤后时间,纵坐标为肿瘤体积,箭头为两次药物注射的时间,表明经过一段时间的药物PPAB001治疗后,较之无关IgG治疗组及anti-CD24组或CV1-hFc组,PPAB001组的肿瘤并未消退。以上实验结果表明,PPAB001可以有效抑制荷瘤小鼠身上乳腺癌和卵巢癌的肿瘤生长,且其抑瘤效果显著强于anti-CD24组、CV1-hFc组和IgG对照组,但PPAB001不能抑制荷瘤小鼠体内的胃癌肿瘤生长。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之做一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (10)
1.靶向CD24和CD47的双特异性抗体融合蛋白,其特征在于,所述融合蛋白包含CD24抗体重链、CD24抗体轻链以及CD47-Fc结合肽;
其中,CD24抗体重链的恒定区与CD47-Fc结合肽的Fc段通过“锁钥结构”连接;
所述融合蛋白能够同时与CD47、CD24结合。
2.根据权利要求1所述的融合蛋白,其特征在于,所述CD24抗体轻链包含SEQ ID NO:14所示的氨基酸序列,所述CD24抗体重链包含SEQ ID NO:16所示的氨基酸序列,所述CD47-Fc结合肽包含SEQ ID NO:18所示的氨基酸序列。
3.权利要求1或2所述融合蛋白的制备方法,其特征在于,包括如下步骤:
S1、分别构建含有SEQ ID NO:13、SEQ ID NO:15及SEQ ID NO:17所示的核苷酸序列的载体,并将其共转染至宿主细胞中进行培养,筛选稳定表达目标融合蛋白的细胞克隆;
S2、对细胞培养物进行分离纯化,得到目标融合蛋白。
4.根据权利要求3所述的方法,其特征在于,所述载体为真核表达载体pcDNA3.1。
5.根据权利要求3所述的方法,其特征在于,所述宿主细胞为CHO-K1细胞。
6.根据权利要求3~5任一项所述的方法,其特征在于,用含600μg/mL G418和250μg/mLZeocin的选择培养基筛选稳定表达目标融合蛋白的细胞克隆。
7.编码权利要求1或2所述融合蛋白的核酸分子。
8.含有权利要求7所述核酸分子的生物材料,其特征在于,所述生物材料为重组DNA、表达盒、转座子、质粒载体、病毒载体、工程菌或转基因细胞系。
9.含有权利要求1或2所述融合蛋白的组合物,所述组合物任选包含抗肿瘤制剂;
优选地,所述抗肿瘤制剂选自如下A~E中的至少一种:
A、细胞毒类药物,包括:(1)作用于DNA化学结构的药物:烷化剂优选氮芥类、亚硝尿类、甲基磺酸酯类;铂类化合物优选顺铂、卡铂和草酸铂;丝裂霉素;(2)影响核酸合成的药物:二氢叶酸还原酶抑制剂,优选甲氨喋呤和Alimta;胸腺核苷合成酶抑制剂优选氟尿嘧啶类;嘌呤核苷合成酶抑制剂,优选6-巯基嘌呤和6-TG;核苷酸还原酶抑制剂,优选羟基脲;DNA多聚酶抑制剂,优选阿糖胞苷和健择;(3)作用于核酸转录的药物,优选放线菌素D、柔红霉素、阿霉素、表阿霉素、阿克拉霉素、光辉霉素;(4)作用于微管蛋白合成的药物,优选紫杉醇、泰索帝、长春花碱、长春瑞滨、鬼臼硷类、高三尖杉酯碱;(5)其他细胞毒药,优选门冬酰胺酶;
B、激素类药物,包括:(1)抗雌激素,优选三苯氧胺、屈洛昔芬、依西美坦;(2)芳香化酶抑制剂,优选氨鲁米特、兰特隆、来曲唑、瑞宁德;抗雄激素:(3)氟它氨RH-LH激动剂/拮抗剂,优选诺雷德、依那通;
C、生物反应调节剂:包括:(1)干扰素,优选白细胞介素-2;(2)胸腺肽类;
D、单克隆抗体,优选西妥昔Cetuximab;赫赛汀单抗,贝伐单抗;
E、其他药物:包括:(1)细胞分化诱导剂,优选维甲类;(2)细胞凋亡诱导剂。
10.权利要求1或2所述融合蛋白或者权利要求9所述组合物在制备抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310421574.5A CN116606377A (zh) | 2023-04-19 | 2023-04-19 | 靶向cd24和cd47的双特异性抗体融合蛋白及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310421574.5A CN116606377A (zh) | 2023-04-19 | 2023-04-19 | 靶向cd24和cd47的双特异性抗体融合蛋白及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116606377A true CN116606377A (zh) | 2023-08-18 |
Family
ID=87678987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310421574.5A Pending CN116606377A (zh) | 2023-04-19 | 2023-04-19 | 靶向cd24和cd47的双特异性抗体融合蛋白及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116606377A (zh) |
-
2023
- 2023-04-19 CN CN202310421574.5A patent/CN116606377A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190321466A1 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
US10906983B2 (en) | Anti-CD137 antibodies | |
EP3838289A1 (en) | Anti-tigit antibody and uses thereof | |
EP1871807B1 (en) | Antibodies against cxcr4 and methods of use thereof | |
TW201425338A (zh) | 雙特異性抗體 | |
EA023665B1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
EP4273167A1 (en) | Anti-cldn18.2 antibody, and preparation method therefor and use thereof | |
TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
US20230279134A1 (en) | Anti-cd137 antibodies | |
JP2023544143A (ja) | 抗クローディン18.2および抗cd3二重特異性抗体およびその使用 | |
JP2022521958A (ja) | 抗pd-l1抗体及びその応用 | |
CN114667297A (zh) | 一种抗体融合蛋白及其制法和在抗肿瘤中的应用 | |
CN112041346A (zh) | 用于与抗pd-1抗体组合的抗cd137抗体 | |
WO2021214329A1 (en) | Composition comprising an ige antibody | |
CN114380915A (zh) | 抗cd73的抗体及其用途 | |
US11912777B2 (en) | Antibodies binding TNFR2 and uses thereof | |
US20230279130A1 (en) | Anti-ccr8 antibodies | |
WO2022242758A1 (zh) | 抗cd73抗体及其应用 | |
WO2023001155A1 (zh) | 一种磷脂酰肌醇蛋白聚糖3抗体及其应用 | |
WO2022194201A1 (zh) | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 | |
EP4234579A1 (en) | Anti-cd73 antibody and use thereof | |
EP4242232A1 (en) | Bispecific antibody and use thereof | |
US20230287126A1 (en) | Anti-pd-l1 antibody and use thereof | |
CN116606377A (zh) | 靶向cd24和cd47的双特异性抗体融合蛋白及其制备方法与应用 | |
US11512134B2 (en) | Anti-CD137 antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |